



Emergent BioSolutions Receives Loan Repayment from Protein Sciences Corporation

November 3, 2010

ROCKVILLE, Md., Nov 03, 2010 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has received repayment of the loan it extended to Protein Sciences Corporation in 2008. The total payment of \$11.5 million includes full repayment of the original \$10 million in principal plus \$1.5 million in accrued interest. In addition, the parties signed a mutual settlement and release agreement that dismisses all litigation between both parties.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a global biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body's immune system to prevent or treat disease. Emergent's marketed and investigational products target infectious diseases, oncology, and autoimmune disorders. Additional information about the company may be found at <http://www.emergentbiosolutions.com>.

SOURCE: Emergent BioSolutions Inc.

Emergent BioSolutions Inc.

Investors Contact:

Robert G. Burrows, **301-795-1877**

Vice President, Investor Relations

BurrowsR@ebsi.com

or

Media Contact:

Tracey Schmitt, **301-795-1800**

Vice President, Corporate Communications

SchmittT@ebsi.com